SS
AVBP icon

SBI Securities’s ArriVent BioPharma AVBP Stock Holding History

SBI Securities’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$903 Hold
26
– – ﹤0.01% 2840
2026
Q1 		$600 Sell
26
-20
-43% -$452 ﹤0.01% 2819
2025
Q4 		$926 Sell
46
-2
-4% -$42 ﹤0.01% 2672
2025
Q3 		$886 Buy
48
+23
+92% +$452 ﹤0.01% 2747
2025
Q2 		$544 Hold
25
– – ﹤0.01% 2934
2025
Q1 		$462 Hold
25
– – ﹤0.01% 2900
2024
Q4 		$666 Buy
+25
New +$718 ﹤0.01% 2787

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SBI Securities's AVBP Position: Q2 2026 in Review

SBI Securities held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 26 shares worth $903. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

SBI Securities first reported a position in AVBP in Q4 2024 and has held it in 7 quarters since. The position peaked at $926 in Q4 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • SBI Securities held 26 shares of ArriVent BioPharma worth $903 as of Q2 2026.
  • SBI Securities left its ArriVent BioPharma share count unchanged in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2840 holding.
  • SBI Securities first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's ArriVent BioPharma position peaked at $926 in Q4 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.